GC Biopharma Q3 Operating Profit Rises 68.5% Year Over Year
Bitget2026/11/02 00:07- GC Biopharma's third-quarter 2026 operating profit rose 68.5% year over year to KRW 49.2 billion.
- Revenue fell 14.3% year over year to KRW 522.1 billion.
- Net profit surged 1,051.9% year over year to KRW 208.5 billion.
- Nine-month operating profit declined 2.8% to KRW 62.7 billion.
- Revenue for the nine months dropped 7.7% to KRW 1.38 trillion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
